Core Viewpoint - Predictmedix AI Inc. successfully closed the first tranche of its non-brokered private placement, raising gross proceeds of $460,150 by issuing 9,203,000 units at a price of $0.05 per unit, indicating strong internal confidence in the company's future growth and innovation [1][2]. Financing Details - The private placement consisted of 9,203,000 units, each comprising one common share and one half of a common share purchase warrant, raising a total of $460,150 [2]. - Insiders subscribed $60,000 of the tranche, with Sheldon Kales and Dr. Rahul Kushwah each investing $30,000, reflecting confidence in the company's prospects [1][3]. - Each warrant allows the holder to purchase one half of a common share at a price of C$0.15 for 36 months, with potential acceleration of expiry if the share price meets certain conditions [2]. Regulatory Context - The insider participation in the private placement is classified as a "related party transaction" under Multilateral Instrument 61-101, with the company relying on exemptions from valuation and minority shareholder approval requirements [3]. Strategic Engagement - This financing round follows Predictmedix's active engagement with European capital markets, including participation in the 25th MK Investment Conference in Munich, aimed at expanding its shareholder base and building relationships with global investors [5]. - The company has also conducted a high-profile European road-show to engage influential family offices and institutional investors [5]. Company Overview - Predictmedix AI Inc. is an emerging provider of rapid health screening and remote patient care solutions, utilizing AI technology to analyze physiological data and predict various health issues [6]. - The company's Smarthealth AI stations can assess 19 physiological vital parameters and detect impairments due to drugs or alcohol, fatigue, or mental illnesses [6].